Molnupiravir for treatment of COVID-19 in solid organ transplant recipients
Solid organ transplant recipients (SOTRs) are at a higher risk of progression of coronavirus
disease 2019 (COVID-19). 1, 2 With the emergence of new viralvariants, the currently …
disease 2019 (COVID-19). 1, 2 With the emergence of new viralvariants, the currently …
[HTML][HTML] Current status of oral antiviral drug treatments for SARS-CoV-2 infection in non-hospitalized patients
DV Parums - … science monitor: international medical journal of …, 2022 - ncbi.nlm.nih.gov
On 4 th November 2021, the first oral antiviral drug for COVID-19, molnupiravir (Lagevrio®),
received full regulatory approval from the Medicines and Healthcare Products Regulatory …
received full regulatory approval from the Medicines and Healthcare Products Regulatory …
Molnupiravir: from hope to epic fail?
D Focosi - Viruses, 2022 - mdpi.com
Molnupiravir has been the first oral antiviral authorized for COVID-19 outpatients, reporting
extraordinary sales and preserved in vitro efficacy against Omicron sublineages so far …
extraordinary sales and preserved in vitro efficacy against Omicron sublineages so far …
A phase I, randomized, placebo‐controlled study of molnupiravir in healthy Japanese to support special approval in Japan to treat COVID‐19
K Nakamura, K Fujimoto, C Hasegawa… - Clinical and …, 2022 - Wiley Online Library
Abstract Molnupiravir (MK‐4482) is an oral prodrug of the antiviral ribonucleoside analog, N‐
hydroxycytidine (NHC), which has activity against RNA viruses, including severe acute …
hydroxycytidine (NHC), which has activity against RNA viruses, including severe acute …
Response to" Dose Rationale for Favipiravir Use in Patients Infected With SARS‐CoV‐2"
YX Du, XP Chen - Clinical Pharmacology and Therapeutics, 2020 - ncbi.nlm.nih.gov
Dear Editor, We appreciate the letter by Eloy et al. for their comments and complement
regarding our review. 1, 2 Two independent in vitro studies indicated that favipiravir (T-705) …
regarding our review. 1, 2 Two independent in vitro studies indicated that favipiravir (T-705) …
Molnupiravir when used alone seems to be safe and effective as outpatient COVID-19 therapy for hemodialyzed patients and kidney transplant recipients
P Poznański, H Augustyniak-Bartosik, A Magiera-Żak… - Viruses, 2022 - mdpi.com
Background: Molnupiravir demonstrated an in vitro antiviral activity against positive-sense
RNA viruses, including SARS-CoV-2. The study aimed to present the results of outpatient …
RNA viruses, including SARS-CoV-2. The study aimed to present the results of outpatient …
Human safety, tolerability, and pharmacokinetics of a novel broad-spectrum oral antiviral compound, molnupiravir, with activity against SARS-CoV-2
WP Painter, W Holman, JA Bush, F Almazedi, H Malik… - medrxiv, 2020 - medrxiv.org
Abstract Molnupiravir, EIDD-2801/MK-4482, the prodrug of the ribonucleoside analog ß-d-
N4-hydroxycytidine (NHC), has activity against a number of RNA viruses including severe …
N4-hydroxycytidine (NHC), has activity against a number of RNA viruses including severe …
Real-world experience of the comparative effectiveness and safety of molnupiravir and nirmatrelvir/ritonavir in high-risk patients with COVID-19 in a community setting
Y Mutoh, T Umemura, T Nishikawa, K Kondo, Y Nishina… - Viruses, 2023 - mdpi.com
Molnupiravir (MOV) and nirmatrelvir/ritonavir (NMV/r) are efficacious oral antiviral agents for
patients with the 2019 coronavirus (COVID-19). However, little is known about their …
patients with the 2019 coronavirus (COVID-19). However, little is known about their …
The preclinical discovery and development of molnupiravir for the treatment of SARS-CoV-2 (COVID-19)
P Pagliano, C Sellitto, T Ascione… - Expert Opinion on …, 2022 - Taylor & Francis
Introduction Molnupiravir (MOV) is a broad-spectrum oral antiviral agent approved for the
treatment of COVID-19. The results from in vitro and in vivo studies suggested MOV activity …
treatment of COVID-19. The results from in vitro and in vivo studies suggested MOV activity …